RxDoctor Payments Data

Mark Storey, MD

Radiation Oncology · Little Rock, ARNPI 1578550851

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Raysearch Laboratories AB (publ) at 27.3% of the total. Reporting peaked in 2019 at $699 and has fallen 72.9% since, to $190 in 2025.

$1,779in general payments, 2019–2025

Across 25 payments — averaging $71.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Raysearch Laboratories AB (publ)$485
  • Boston Scientific$428
  • Teleflex LLC$324
  • Reflexion Medical, Inc.$213
  • Accuray Incorporated$119
  • Novocure Inc.$54
  • plus $156 from 4 others

What the payments were for

  • Food & beverage$1,779100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Raysearch Laboratories AB (publ)1$485
Boston Scientific10$428
Teleflex LLC6$324
Reflexion Medical, Inc.1$213
Accuray Incorporated1$119
Novocure Inc.2$54
Ion Beam Applications S.A.1$51
Sumitomo Pharma America, Inc.1$46
Medtronic1$35
Visionrt, Inc.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,779 in reported general payments places this provider in the 70th percentile of 45 radiation oncology providers in Arkansas.

See all radiation oncology providers in Arkansas

Medicare billing

Part B allowed, 2024
$1,567,165
Medicare patients
435
Services billed
5,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl132$1,690

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →